Fluordx LLC v. Quidel Corporation

District Court, S.D. California·Decided August 4, 2020·No. 3:19-cv-01998·Unknown

Opinion

FLUORDX LLC, Case No.: 19-CV-1998 JLS (JLB)

Plaintiff, ORDER GRANTING IN PART AND v. DENYING IN PART DEFENDANT’S MOTION TO DISMISS

Defendant. (ECF No. 13) Presently before the Court is Defendant Quidel Corporation’s Motion to Dismiss (“MTD,” ECF No. 13). Also before the Court are Plaintiff FluorDx LLC’s Response in Opposition to (“Opp’n,” ECF No. 14) and Defendant’s Reply in Support of (“Reply,” ECF No. 15) the Motion. After considering Plaintiff’s Complaint, the Parties’ arguments, and the law, the Court GRANTS IN PART and DENIES IN PART Defendant’s Motion. Plaintiff FluorDx, LLC is a California limited liability corporation located in Carlsbad, California. Compl. ¶ 3, ECF No. 1. Plaintiff is the owner by assignment of U.S. Patent Number 9,274,056 (the “’056 Patent”), issued on March 1, 2016. Id. ¶ 5. The ’056 Patent describes an “assay method for detecting the presence of an analyte in a sample using a test strip and then analyzing this strip in a reader that uses an LED light source as the UV excitation source.” Id. ¶ 12. Defendant Quidel Corporation is a Delaware corporation licensed to do business in California and headquartered in San Diego, California. Id. ¶ 4. Defendant manufactures and sells the Sofia and Sofia 2 immunoassay test systems. See id. ¶ 8. The Sofia system, released in 2011, “use[s] lanthanide fluorochrome particles embedded in particles to test for the presence of various analytes. This system or method uses a lateral flow test strip with lanthanide fluorochrome particles to detect the desired analyte and the test strip is then placed into the Sofia reader, which uses an LED light source to excite fluorescent emission and quantify the result.” Id. The Sofia 2 system, released in 2018, is an upgrade to the original Sofia system. Id. Plaintiff filed its Complaint on October 17, 2019. See generally id. Plaintiff alleges Defendant’s Sofia assay systems directly and indirectly infringe Claims 1, 2, 3, 4, 5, 6, 10, 11, 12, 14, 17, 18, and 20 of the ’056 patent. Id. ¶¶ 26–38. After being served with the Complaint, Defendant filed the Motion now before the Court. See generally Mot. A 12(b)(6) motion to dismiss tests the legal sufficiency of the complaint. Fed. R. Civ. P. 12(b)(6); Navarro v. Block, 250 F.3d 729, 732 (9th Cir. 2001). The pleading standard requires only “a short and plain statement of the claim showing that the pleader is entitled to relief.” Fed. R. Civ. P. 8(a)(2). To survive a motion to dismiss, however, the claim to relief must be “plausible on its face.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 570 (2007). Although a complaint need not contain “detailed factual allegations,” it must provide more than “‘naked assertions’ devoid of ‘further factual enhancement.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Twombly, 550 U.S. at 555–57). Mere “labels and conclusions, and a formulaic recitation of the elements of a cause of action will not do.” Twombly, 550 U.S. at 555. When considering a 12(b)(6) motion, the court must accept all material allegations of the complaint and “construe[ them] in the light most favorable to the nonmoving party.” Cahill v. Liberty Mut. Ins. Co., 80 F.3d 336, 337–38 (9th Cir. 1996). The court need not assume the truth of “legal conclusions” or “assume that ‘the [plaintiff] can prove facts that [he or she] has not alleged.’” Naigan v. Nana Servs., LLC, No. 12-cv-2648 BAS (NLS), 2015 WL 300368, at *1 (S.D. Cal. Jan. 22, 2015) (alterations in original) (citing Assoc. Gen. Contractors of Cal. v. Cal. State Council of Carpenters, 459 U.S. 519, 526 (1983)). Dismissal may be based on the absence of a cognizable legal theory, or failure to allege sufficient facts to support a cognizable legal theory. Balistreri v. Pacifica Police Dept., 901 F.2d 696, 699 (9th Cir. 1988). Upon dismissal, the district court should grant leave to amend unless “the pleading could not possibly be cured by the allegation of other facts.” Lopez v. Smith, 203 F.3d 1122, 1130 (9th Cir. 2000). When considering claims for infringement of a patent, the pleading standards under Twombly and Iqbal govern. Footbalance Sys. Inc. v. Zero Gravity Inside, Inc., No. 15-CV-1058 JLS (DHB), 2016 WL 5786936, at *2–3 (S.D. Cal. Oct. 4, 2016). Defendant argues that Plaintiff has not plausibly alleged its claims for (1) direct infringement, (2) indirect infringement, or (3) willful infringement. Mot. at 11–17. The Court considers each argument in turn. I. Direct Infringement Plaintiff’s first claim against Defendant is for direct infringement under 35 U.S.C. § 271(a), for “making, using, importing, offering to sell and selling in the United States the Quidel Sofia and Sofia 2 assay systems.” Compl. ¶ 23. To state a claim for direct patent infringement, a plaintiff must allege that the defendant, “without authority[,] makes, uses, offers to sell, or sells any patented invention.” 35 U.S.C. § 271(a); see also Joy Techs., Inc. v. Flakt, Inc., 6 F.3d 770, 773 (Fed. Cir. 1993) (citing Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1469 (Fed. Cir. 1990), cert. denied, 493 U.S. 1076 (1990)). “To prove infringement, the patentee must show that an accused product embodies all limitations of the claim either literally or by the doctrine of equivalents.” Cephalon, Inc. v. Watson Pharms., Inc., 707 F.3d 1330, 1340 (Fed. Cir. 2013). “To establish literal infringement, every limitation set forth in a claim must be found in the accused product, exactly.” Advanced Steel Recovery, LLC v. X-Body Equip., Inc., 808 F.3d 1313, 1319 (Fed. Cir. 2015) (citing Southwall Techs., Inc. v. Cardinal IG Co., 54 F.3d 1570, 1575 (Fed. Cir. 1995)). “Under the doctrine of equivalents, ‘a product or process that does not literally infringe upon the express terms of a patent claim may nonetheless be found to infringe if there is “equivalence” between the elements of the accused product or process and the claimed elements of the patented invention.’” DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc., 469 F.3d 1005, 1016 (Fed. Cir. 2006) (citing Warner–Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 21 (1997)). Defendant contends Plaintiff fails to show that every limitation in Claim 1 of the ’056 patent can be found in the accused

Free access — add to your briefcase to read the full text and ask questions with AI

Fluordx LLC v. Quidel Corporation, (S.D. Cal. 2020).

Fluordx LLC v. Quidel Corporation (Fluordx LLC v. Quidel Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Warner-Jenkinson Co. v. Hilton Davis Chemical Co.
520 U.S. 17 (Supreme Court, 1997)
Watters v. Wachovia Bank, N. A.
550 U.S. 1 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Fujitsu Limited v. Netgear Inc.
620 F.3d 1321 (Federal Circuit, 2010)
Vita-Mix Corp. v. Basic Holding, Inc.
581 F.3d 1317 (Federal Circuit, 2009)
Southwall Technologies, Inc. v. Cardinal Ig Company
54 F.3d 1570 (Federal Circuit, 1995)
Cephalon, Inc. v. Watson Pharmaceuticals, Inc.
707 F.3d 1330 (Federal Circuit, 2013)
Fujitsu Ltd. v. Belkin International, Inc.
782 F. Supp. 2d 868 (N.D. California, 2011)
Advanced Steel Recovery, LLC v. X-Body Equipment, Inc.
808 F.3d 1313 (Federal Circuit, 2015)
Wbip, LLC v. Kohler Co.
829 F.3d 1317 (Federal Circuit, 2016)
Lopez v. Smith
203 F.3d 1122 (Ninth Circuit, 2000)
Navarro v. Block
250 F.3d 729 (Ninth Circuit, 2001)